Jincheng Pharm(SZ:300233) Jing Ji Guan Cha Wang·2026-02-13 01:55Core Insights - Company plans to select seven products, including Ceftriaxone Sodium Injection, in the national drug centralized procurement, which is expected to enhance its market share in core antibiotic products [1][2] - The sales revenue of these products is approximately 414 million yuan, accounting for 21.45% of the company's total revenue for the first three quarters of 2025 [1][2] - The procurement cycle is anticipated to run from the end of March 2026 to the end of December 2028 [2] Recent Events - On February 11, 2026, the company announced that its subsidiaries are set to be selected for the procurement of seven products, which will help consolidate its market position [2] - The company’s subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, which may provide tax benefits and policy support for three years [2] - As of January 30, 2026, the number of shareholders has slightly increased to 29,200, reflecting a 0.31% growth, with an average shareholding value rising by 1.68% [2] Stock Performance - Over the past week (February 6 to 12, 2026), the company's stock price fluctuated between 15.30 yuan and 15.29 yuan, with a slight overall decline and a price range fluctuation of 2.32% [3] - As of February 12, 2026, the stock price was 15.29 yuan, down 1.55%, underperforming the pharmaceutical and biotechnology sector, which fell by 0.60% [3] - Recent capital flow indicates a net outflow of major funds, with a net outflow of 8.5 million yuan on February 12, while small and medium-sized investments showed a net inflow, indicating higher retail investor participation [3]